Products
Vanucizumab Biosimilar Bispecific Antibody (ANGPT2 × VEGF-A) for Research
Pre-Made Vanucizumab biosimilar, Bispecific mAb, Anti-ANGPT2;VEGFA Antibody: Anti-AGPT2/ANG2/LMPHM10;VPF/VEGF/MVCD1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Vanucizumab (INN; development code RG7221) is an experimental humanized monoclonal antibody designed for the treatment of cancer.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-ab-612-1mg | 1mg | |
| GMP-Bios-ab-612-10mg | 10mg | |
| GMP-Bios-ab-612-100mg | 100mg | |
| GMP-Bios-ab-612-xmg | ＞100mg |
Product Details
| Products Name (INN Index) | Pre-Made Vanucizumab biosimilar, Bispecific mAb, Anti-ANGPT2;VEGFA Antibody: Anti-AGPT2/ANG2/LMPHM10;VPF/VEGF/MVCD1 therapeutic antibody |
| INN Name | Vanucizumab |
| Target | ANGPT2;VEGFA |
| Format | Bispecific mAb |
| Derivation | Bispecific antibody |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Lambda;Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | 4imk:AD:BC/4iml:HL:AB;1bj1:HL:KJ |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;6bft:AB:HL/1cz8:HL:YX |
| Year Proposed | 2014 |
| Year Recommended | 2015 |
| Companies | Roche |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Solid tumours;Colorectal cancer |
| Development Tech | na |
About target - ANGPT2
1. Protein Angiopoietin-2
2. Gene ANGPT2
3. Organism Homo sapiens (Human)
Function
Binds to TEK/TIE2, competing for the ANGPT1 binding site, and modulating ANGPT1 signaling. Can induce tyrosine phosphorylation of TEK/TIE2 in the absence of ANGPT1. In the absence of angiogenic inducers, such as VEGF, ANGPT2-mediated loosening of cell-matrix contacts may induce endothelial cell apoptosis with consequent vascular regression. In concert with VEGF, it may facilitate endothelial cell migration and proliferation, thus serving as a permissive angiogenic signal.
